<DOC>
	<DOC>NCT02551315</DOC>
	<brief_summary>This multicenter, prospective, observational cohort study will assess bone differences in women and men with type 2 diabetes mellitus (T2DM) with and without fragility fractures.</brief_summary>
	<brief_title>Microarchitecture, Bone Strength and Fracture Risk in Type 2 Diabetes</brief_title>
	<detailed_description>Cross-sectional evaluation of clinical, biochemical and microstructural measures of bone in patients with type 2 diabetes and age-matched healthy controls. Longitudinal assessment of clinical, biochemical and microstructural measures of bone in study participants without prevalent fragility fractures.</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Fractures, Bone</mesh_term>
	<criteria>presence of type 2 diabetes for at least 3 years (history of treatment for type 2 diabetes) immobility coexisting metabolic bone disease or comorbidities affecting bone health previous treatment with osteoporosis medication or intake of medications known to affect bone metabolism (e.g. steroids) within 6 months prior to enrolment thiazolidinedione use</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Intra-cortical pore volume</keyword>
	<keyword>HR-pQCT</keyword>
	<keyword>DXA</keyword>
	<keyword>bone mineral density</keyword>
	<keyword>bone turnover markers</keyword>
	<keyword>urinary pentosidine</keyword>
</DOC>